Abstract
The non-selective activation of central and peripheral opioid receptors is a major shortcoming of currently available opioids. Targeting peripheral opioid receptors is a promising strategy to preclude side effects. Recently, we showed that fentanyl-derived μ-opioid receptor (MOR) agonists with reduced acid dissociation constants (pKa) due to introducing single fluorine atoms produced injury-restricted antinociception in rat models of inflammatory, postoperative and neuropathic pain. Here, we report that a new double-fluorinated compound (FF6) and fentanyl show similar pKa, MOR affinity and [35S]-GTPγS binding at low and physiological pH values. In vivo, FF6 produced antinociception in injured and non-injured tissue, and induced sedation and constipation. The comparison of several fentanyl derivatives revealed a correlation between pKa values and pH-dependent MOR activation, antinociception and side effects. An opioid ligand’s pKa value may be used as discriminating factor to design safer analgesics.
Cite
CITATION STYLE
Del Vecchio, G., Labuz, D., Temp, J., Seitz, V., Kloner, M., Negrete, R., … Stein, C. (2019). pKa of opioid ligands as a discriminating factor for side effects. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-55886-1
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.